Business Context and Reporting Period
Company: OrthoLogic Corp. (Note: Metadata listed "Capstone Holding Corp." but filing text confirms registrant is OrthoLogic Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1999
Business Overview: OrthoLogic develops and markets orthopedic products, including the OL-1000 Bone Growth Stimulator, Continuous Passive Motion (CPM) devices, and Hyalgan (via co-promotion with Sanofi). The company is also pursuing the development of Chrysalin for fracture healing.
Key Financial Metrics
| Metric | Q2 1999 (3 Months) | Q2 1998 (3 Months) | YTD 1999 (6 Months) | YTD 1998 (6 Months) |
|---|---|---|---|---|
| Revenues | $20.7 million | $17.5 million | $41.8 million | $36.6 million |
| Gross Profit | $16.1 million | $13.3 million | $32.5 million | $28.0 million |
| Gross Margin | 78% | 76% | 78% | 76% |
| Operating Loss | $(0.2) million | $(3.9) million | $(0.1) million | $(13.2) million |
| Net Loss | $(0.2) million | $(3.9) million | $(0.04) million | $(13.0) million |
| Net Loss to Common Shareholders | $(0.4) million | $(3.9) million | $(0.9) million | $(13.0) million |
| Cash Flow from Operations | N/A | N/A | $0.1 million | $(5.9) million |
| Cash & Investments (End of Period) | $3.9 million | N/A | $3.9 million | $7.8 million (Dec 31, 1998) |
| Debt Facilities | $7.5M AR Revolver + $2.5M Term Loan (Max $10M); Current borrowings minimal. |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 18% in Q2 and 14% YTD compared to 1998, driven by higher demand for CPM products and Hyalgan co-promotion fees.
- Profitability Improvement: Operating loss narrowed significantly from $3.9 million in Q2 1998 to $0.2 million in Q2 1999. YTD operating loss decreased from $13.2 million to $0.1 million.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses dropped 22% YTD. This was primarily due to the absence of a $1.0 million legal settlement expense and a $9.3 million bad debt charge recorded in Q1 1998.
- Liquidity: Cash and short-term investments decreased from $7.8 million (Dec 31, 1998) to $3.9 million (June 30, 1999). This decline was attributed to a $1.0 million payment on the Sanofi co-promotion agreement, a $0.75 million payment to Chrysalis, and a $2.3 million increase in accounts receivable.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates current cash, operating cash flow, and available credit lines ($10M total capacity) will be sufficient for the next 12 months. Long-term funding depends on revenue growth and profitability.
- Product Pipeline: The company is pursuing FDA approval for Chrysalin (fracture healing), with a projected market introduction in 2003. The company elected not to exercise its option for worldwide (non-US) rights to Chrysalin.
- Legal Proceedings:
- Securities Litigation: A federal class action regarding the OL-1000 Bone Growth Stimulator was largely dismissed in March 1999, though narrow insider trading claims against individuals remain. A parallel state court case is proceeding with discovery.
- False Claims Settlement: A $1.0 million settlement with the DOJ regarding false claims was expensed in Q2 1998 (not 1999).
- Year 2000 Compliance: The company believes it is compliant, with costs to date under $100,000. The primary risk identified is the potential failure of third-party payors to be Y2K compliant, which could interrupt cash payments.
- Unusual Items: The financial statements include non-cash accretion of preferred stock dividends ($0.8 million YTD) related to the Series B Convertible Preferred Stock issued in 1998.
Investor Verification Checklist
- Cash Burn vs. Runway: Verify if the $3.9 million cash balance and $10 million credit line are sufficient given the $0.9 million YTD net loss and ongoing R&D costs for Chrysalin.
- Accounts Receivable Quality: Confirm the $2.3 million increase in receivables is collectible, given the company's history of significant bad debt charges (e.g., $9.3 million in Q1 1998).
- Chrysalin Development Costs: Assess the magnitude of future capital required to complete clinical trials for Chrysalin, as the filing notes "significant additional costs will be necessary."
- Legal Exposure: Monitor the status of the remaining state court litigation and insider trading claims, as management cannot currently estimate potential costs.
- Preferred Stock Conversion: Review the terms of the $15 million Series B Convertible Preferred Stock, specifically the conversion price and mandatory redemption triggers.